- Home
- HITI vs INBX Comparison
HITI vs INBX Comparison
Compare HITI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HITI
- INBX
- Stock Information
- Founded
- HITI 2009
- INBX 2010
- Country
- HITI Canada
- INBX United States
- Employees
- HITI N/A
- INBX N/A
- Industry
- HITI
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- HITI
- INBX Health Care
- Exchange
- HITI Nasdaq
- INBX Nasdaq
- Market Cap
- HITI 217.9M
- INBX 168.1M
- IPO Year
- HITI N/A
- INBX 2020
- Fundamental
- Price
- HITI $2.39
- INBX $11.26
- Analyst Decision
- HITI Strong Buy
- INBX Hold
- Analyst Count
- HITI 1
- INBX 1
- Target Price
- HITI $4.50
- INBX N/A
- AVG Volume (30 Days)
- HITI 452.2K
- INBX 102.3K
- Earning Date
- HITI 06-12-2025
- INBX 05-20-2025
- Dividend Yield
- HITI N/A
- INBX 7.37%
- EPS Growth
- HITI N/A
- INBX N/A
- EPS
- HITI N/A
- INBX 112.62
- Revenue
- HITI $370,825,186.00
- INBX $200,000.00
- Revenue This Year
- HITI $12.43
- INBX N/A
- Revenue Next Year
- HITI $11.39
- INBX N/A
- P/E Ratio
- HITI N/A
- INBX $0.10
- Revenue Growth
- HITI 7.84
- INBX N/A
- 52 Week Low
- HITI $1.57
- INBX $10.80
- 52 Week High
- HITI $3.62
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- HITI 61.36
- INBX 38.99
- Support Level
- HITI $2.33
- INBX $11.73
- Resistance Level
- HITI $2.43
- INBX $12.60
- Average True Range (ATR)
- HITI 0.07
- INBX 0.84
- MACD
- HITI 0.01
- INBX -0.00
- Stochastic Oscillator
- HITI 70.73
- INBX 18.69
About HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, Famous Brandz, and others. The company's reportable operating segments are; Bricks and mortar which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada followed by the United States of America, and other international markets.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.